Chimerix (CMRX) Posts Earnings Results, Beats Expectations By $0.09 EPS

Share on StockTwits

Chimerix (NASDAQ:CMRX) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.09, Fidelity Earnings reports. The business had revenue of $0.37 million for the quarter, compared to analysts’ expectations of $0.97 million. Chimerix had a negative net margin of 1,582.64% and a negative return on equity of 34.94%.

Shares of NASDAQ CMRX traded down $0.17 during midday trading on Friday, reaching $3.32. 84,193 shares of the stock were exchanged, compared to its average volume of 215,341. The stock has a market capitalization of $172.41 million, a price-to-earnings ratio of -2.20 and a beta of 1.20. Chimerix has a twelve month low of $3.11 and a twelve month high of $5.94.

A number of equities research analysts have recently commented on CMRX shares. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a research note on Thursday, October 4th. Cowen reaffirmed a “hold” rating and set a $6.00 price objective on shares of Chimerix in a research note on Thursday, October 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Chimerix in a research note on Friday, September 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $6.75.

Hedge funds and other institutional investors have recently modified their holdings of the company. Leisure Capital Management acquired a new stake in shares of Chimerix during the 3rd quarter worth approximately $108,000. Wells Fargo & Company MN lifted its position in shares of Chimerix by 46.1% during the 1st quarter. Wells Fargo & Company MN now owns 33,569 shares of the biopharmaceutical company’s stock valued at $175,000 after buying an additional 10,598 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Chimerix by 63.3% during the 2nd quarter. Acadian Asset Management LLC now owns 155,067 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 60,087 shares in the last quarter. Spark Investment Management LLC purchased a new position in shares of Chimerix during the 2nd quarter valued at approximately $917,000. Finally, Schwab Charles Investment Management Inc. lifted its position in shares of Chimerix by 18.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 223,189 shares of the biopharmaceutical company’s stock valued at $1,063,000 after buying an additional 35,216 shares in the last quarter. 71.85% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Week Herald and is the property of of Week Herald. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://weekherald.com/2018/11/10/chimerix-cmrx-posts-earnings-results-beats-expectations-by-0-09-eps.html.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Further Reading: Reverse Stock Split

Earnings History for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply